Evolent Health (NYSE:EVH) Stock Price Down 0.5% Following Analyst Downgrade
Evolent Health Inc (NYSE:EVH)’s stock price dropped 0.5% on Tuesday after KeyCorp lowered their price target on the stock from $20.00 to $10.00. KeyCorp currently has an overweight rating on the stock. Evolent Health traded as low as $6.55 and last traded at $6.58, approximately 41,642 shares changed hands during trading. A decline of 98% from the average daily volume of 2,087,676 shares. The stock had previously closed at $6.61.
Other analysts have also recently issued research reports about the stock. Oppenheimer set a $15.00 price objective on shares of Evolent Health and gave the company a “buy” rating in a research note on Wednesday, August 7th. Piper Jaffray Companies restated an “overweight” rating and set a $10.15 target price on shares of Evolent Health in a research report on Wednesday, November 27th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $10.00 target price (down from $16.00) on shares of Evolent Health in a report on Wednesday, November 27th. Cowen set a $18.00 price target on shares of Evolent Health and gave the company a “buy” rating in a research report on Wednesday, August 7th. Finally, Zacks Investment Research lowered Evolent Health from a “buy” rating to a “hold” rating in a research note on Tuesday, August 6th. Two analysts have rated the stock with a hold rating and six have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $13.20.
A number of large investors have recently bought and sold shares of the business. Aperio Group LLC purchased a new stake in shares of Evolent Health in the second quarter valued at about $40,000. ETRADE Capital Management LLC acquired a new position in shares of Evolent Health during the 2nd quarter worth approximately $80,000. DekaBank Deutsche Girozentrale raised its position in shares of Evolent Health by 94.4% during the 2nd quarter. DekaBank Deutsche Girozentrale now owns 12,061 shares of the technology company’s stock worth $95,000 after purchasing an additional 5,856 shares during the last quarter. GABELLI & Co INVESTMENT ADVISERS INC. raised its position in shares of Evolent Health by 38.4% during the 2nd quarter. GABELLI & Co INVESTMENT ADVISERS INC. now owns 15,500 shares of the technology company’s stock worth $123,000 after purchasing an additional 4,300 shares during the last quarter. Finally, NumerixS Investment Technologies Inc purchased a new stake in Evolent Health in the 2nd quarter valued at approximately $125,000.
Evolent Health (NYSE:EVH) last released its quarterly earnings results on Tuesday, November 5th. The technology company reported ($0.09) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.12) by $0.03. Evolent Health had a negative return on equity of 6.93% and a negative net margin of 15.02%. The company had revenue of $220.14 million during the quarter, compared to analysts’ expectations of $217.90 million. During the same period in the previous year, the firm posted ($0.04) earnings per share. The business’s revenue for the quarter was up 46.8% compared to the same quarter last year. On average, equities research analysts anticipate that Evolent Health Inc will post -0.95 EPS for the current fiscal year.
Evolent Health Company Profile (NYSE:EVH)
Evolent Health, Inc, through its subsidiary, Evolent Health LLC, provides health care delivery and payment solutions in the United States. The company operates as a managed services firm that supports health systems and physician organizations in migration toward value-based care and population health management.
Featured Article: What is Call Option Volume?
Receive News & Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related companies with MarketBeat.com's FREE daily email newsletter.